logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5209.produswest2
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5209.produswest2
World Hepatitis Day 2023 | Collections | MSF Science Portal

Viral hepatitis is a major cause of disease and death globally. To mark World Hepatitis Day (July 28th) we present a selection of recent MSF research exploring how to effectively deploy powerful medical tools that could turn the tide on hepatitis C and E—but now reach only a tiny fraction of people who desperately need them, especially in low-resource and emergency settings.

For hepatitis C, where groundbreaking new antiviral drugs can cure nearly all patients, MSF is piloting simplified, community-based models of care that offer rapid screening, diagnosis, and treatment under one roof. Some programs focus on the complex needs of highly vulnerable, hard-to-reach populations, such as people co-infected with HIV or TB or who inject drugs.

Turning to prevention, an ongoing vaccination campaign against hepatitis E in an outbreak setting is showing early signs of short-term protection. Final results from this South Sudanese refugee camp, where poor sanitation and water quality regularly lead to outbreaks, should help plug a key evidence gap that—along with other barriers discussed in a commentary article—impedes widespread uptake of the vaccine.

Collection Content

Conference Material
|
Abstract

Safety of hepatitis E vaccination in pregnancy following the first mass reactive vaccination campaign in Bentiu, South Sudan

Nesbitt RC
2023-06-08 • Epicentre Scientific Day Paris 2023
2023-06-08 • Epicentre Scientific Day Paris 2023
BACKGROUND
Hepatitis E causes high mortality among pregnant women with case fatality risks of 10-25%, and adverse fetal outcomes. Hecolin® is a safe and efficacious vaccine against H...
Conference Material
|
Slide Presentation

Two-dose vaccine effectiveness following the first reactive mass vaccination campaign against Hepatitis E in Bentiu, South Sudan

Nesbitt RC, Rumunu J, Asilaza VK, Gitahi P, Nkemenang P,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Journal Article
|
Research

Nurse-led initiation of hepatitis C care in rural Cambodia

O’Keefe D, Samley K, Bunreth V, Marquardt T, Bobi SE,  et al.
2023-04-01 • Bulletin of the World Health Organization
2023-04-01 • Bulletin of the World Health Organization
OBJECTIVE
To determine whether a nurse-led model of care for patients with hepatitis C virus (HCV) infections can provide safe and effective diagnosis and treatment in a resource-poo...
Journal Article
|
Research

Hepatitis C treatment program in Maputo, Mozambique, the challenge of genotypes and key populations: A 5-year retrospective analysis of routine programmatic data

Loarec A, Gutierrez AG, Muvale G, Couto AM, Nguyen AP,  et al.
2023-03-30 • Health Science Reports
2023-03-30 • Health Science Reports
BACKGROUND AND AIMS
Hepatitis C (HCV) programs face challenges, especially linked to key populations to achieve World Health Organization (WHO) goals of eliminating hepatitis. Médeci...
Journal Article
|
Research

A simplified point-of-service model for hepatitis C in people who inject drugs in South Africa

Saayman E, Hechter V, Kayuni N, Sonderup MW
2023-03-04 • Harm Reduction Journal
2023-03-04 • Harm Reduction Journal

BACKGROUND

Globally, 9% of people who inject drugs (PWID), a key hepatitis C-infected population, reside in sub-Saharan Africa. In South Africa, hepatitis C seroprevalence in PW...

Journal Article
|
Research

Epidemiological characteristics and real-world treatment outcomes of hepatitis C among HIV/HCV co-infected patients in Myanmar: A prospective cohort study

Swe TM, Johnson DC, Mar HT, Thit P, Homan T,  et al.
2023-02-17 • Health Science Reports
2023-02-17 • Health Science Reports
BACKGROUND AND AIMS
In Myanmar, public sector treatment programs for hepatitis C virus (HCV) infection were nonexistent until June 2017. WHO highlights the importance of simplificati...
Journal Article
|
Commentary

Hepatitis E vaccine—Illuminating the barriers to use

Lynch JA, Lim JK, Asaga PEP, Wartel TA, Marti M,  et al.
2023-01-05 • PLOS Neglected Tropical Diseases
2023-01-05 • PLOS Neglected Tropical Diseases
Journal Article
|
Research

Integrating hepatitis C treatment into multidrug-resistant TB care

Kirakosyan O, Melikyan N, Falcao J, Khachatryan N, Atshemyan H,  et al.
2022-06-21 • Public Health Action
2022-06-21 • Public Health Action
BACKGROUND
Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We d...

See more collections

Our test collection

Our test collection

test

MSF logo

MSF Scientific Days Asia 2024

MSF Scientific Days Asia 2024 is a conference that presents research, innovation, and experiences from treatment and humanitarian programmes across Asia. MSF Scientific Days brings together researchers, practitioners, academics, and patient representatives with the aim to catalyse improvements in the quality of care provided to patients and populations at risk. This is a platform for experts in the humanitarian global health field to come together, collaborate, and discuss the current trends and challenges in innovation and healthcare. 

World Hepatitis Day 2024

World Hepatitis Day 2024

Viral hepatitis is a significant cause of disease and death globally. Yet powerful new medical tools to combat hepatitis C and E still reach only a tiny fraction of people who desperately need them, especially in low-resource and emergency settings.


To mark World Hepatitis Day (July 28th) we highlight recent MSF research on making these breakthrough products more widely accessible and simpler to use.


For hepatitis C, where groundbreaking antiviral drugs can cure nearly all patients, MSF is developing comprehensive, community-based models of care that offer rapid screening, diagnosis, and treatment under one roof. In some settings programs focus on the specific needs of highly vulnerable populations, such as people living in remote areas, forcibly displaced refugees, or those co-infected with HIV or TB or who inject drugs.


Turning to prevention, MSF is exploring ways to use the Hepatitis E vaccine more effectively in areas where poor sanitation and water quality regularly lead to outbreaks. Studies in a South Sudanese camp for internally displaced people are strengthening evidence for the vaccine’s feasibility, efficacy, safety and community acceptance, especially for pregnant women and their fetuses. Another report analyzes strategies for overcoming barriers to widespread vaccine adoption.

View All Collections
World Hepatitis Day 2023

World Hepatitis Day 2023